Low Molecular Weight Heparin (LMWH) Resistance in Cancer Patients

Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.

Thromboembolic complications are a common and costly medical problem, associated with significant morbidity and mortality, especially in postoperative patients. There have been reports of death due to thromboembolic complications even after short procedures, e.g. arthroscopy. Low-molecular-weight heparins (LMWHs) (e.g., certoparin, dalteparin, enoxaparin, nadroparin, reviparin, tinzaparin) have...

Warfarin versus low-molecular-weight heparin therapy in cancer patients.

The association between cancer and venous thromboembolism (VTE) is well established. Importantly, VTE is a significant cause of mortality in cancer patients. Although long-term warfarin (Coumadin(trade mark); Bristol-Myers Squibb; New York, NY) therapy is the mainstay of treatment for cancer patients with VTE, there are many practical problems with its use in this population. In particular, ach...

Low Molecular Weight Heparin Overdose: A 10 Year Case Series

  Background: Low molecular weight heparin (LMWH) is used for the treatment and prevention of coagulative disorders. Few patients receiving therapeutic doses of LMWH develop major hemorrhage. Currently there are few reports in the literature on acute overdose on adults.  In this study, clinical profile, treatment and outcome of 21 patients who acutely overdosed enoxaparin are described. Method...

Low-Molecular-Weight Heparin (LMWH) in Women with Repeated Implantation Failure.

Despite the initial dramatic improvements in success rates and significant increments in uptake of assisted reproduction techniques (ARTs), the live birth rate resulting from these techniques has recently plateaued [1]. Greater emphasis is now being placed on experimental strategies to further improve oocyte and embryo number and quality, implantation rates, and successful transition to live bi...

Low molecular weight heparin.